Dewpoint Therapeutics raise $77m in Series B financingA $77 Series B financing allows Dewpoint Therapeutics Inc to select a lead programme from its new drug class of molecular condensates and push proof-of-concept studies. more ➔
Kurma Partners close diagnostics fund at €50mThe only investment fund dedicated to breakthrough diagnostics, Kurma Diagnostics 2, had its first closing at €50m. more ➔
Danish Galecto Inc. secures US$64m equity financingDanish fibrosis and cancer specialist Galecto Inc. has raised US$64m in a Series B round led by Soleus Capital. more ➔
MosaMeat NV bags US$55m financingMaastricht-based cultured meat producer Mosa Meat NV has raised $55m in a Series B financing, bringing its funding to $63.8m. more ➔
Pureos Bioventures closes US$170m fundNewly formed venture capitalist Pureos Bioventures has set up a US$170m fund dedicated to Swiss and European drug developers. more ➔
Biotechs request money for COVID therapeuticsGerman biotech companies and their industry association BIO Deutschland have called for appropriate investments into clinical COVID-19 therapies. more ➔
Polyneuron Pharmaceuticals AG extends Series A financing Swiss auto-immunity specialist Polyneuron Pharmaceuticals AG has received CHF14m from HBM Healthcare Investments. more ➔
Mabion to licence COVID-19 jab from Vaxine Pty LtdPolish Mabion SA and Australian Vaxine Pty Ltd to develop Covax-19 more ➔
4SC and Maruho end collaboration on Kv1.3 blockersJapanese dermatology specialist Maruho Co. Ltd and drug discovery firm 4SC AG have terminated their development agreement related to 4SC’s blockers of Kv1.3 ion channels, which are required for maintenance … more ➔
MiNA Therapeutic bags £23m financingRNA therapeutics specialist MiNA Therapeutics plc has secured £23m in a Series A financing to push development its first-in-class small activating RNA (saRNA) candidates. more ➔
